Please login to the form below

Not currently logged in
Email:
Password:

Galafold

This page shows the latest Galafold news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

This year, the judges concluded that just two entrants were worthy of being shortlisted for the Innovative Product Award; Sanofi (Dupixent) and Amicus (Galafold). ... Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold),

Latest news

  • Amicus Therapeutics launches Fabry treatment Galafold in Italy Amicus Therapeutics launches Fabry treatment Galafold in Italy

    Amicus Therapeutics launches Fabry treatment Galafold in Italy. Follows publication of Ministry of Health's reimbursement guidelines. ... US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    Amicus gets NICE green light for Fabry drug. Oral therapy alternative Galafold approved for routine NHS use. ... Fabry disease affects an estimated 855 people in England, of whom around 140 would be eligible for treatment with Galafold, according to

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    SMC approves Opdivo combo as first-line skin cancer treatment. Also backs Gilead’ s Epclusa, Baxalta’ s Oncaspar, AZ’ s Lynparza and Amicus’ Galafold. ... Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    The UK's NICE has recommended the use of Galafold (migalastat) on the NHS for the treatment of Fabry disease in draft Highly Specialised Technologies guidance. ... Fabry disease affects an estimated 855 people in England, of whom around 140 would be

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    Amicus Therapeutics got a green light from the CHMP for Galafold (migalastat) as the first oral treatment for Fabry disease, which is caused by a deficiency in alpha-galactosidase A.

More from news
Approximately 5 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics